Goldman Sachs’s Standard BioTools LAB Stock Holding History

Goldman Sachs’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-100,000	Closed	-$807K	–	7142
2016 Q1	$807K	Sell	100,000 -755,000	-88%	-$5.45M	﹤0.01%	4271
2015 Q4	$9.24M	Hold	855,000	–	–	﹤0.01%	2314
2015 Q3	$6.93M	Buy	+855,000	New	+$13.5M	﹤0.01%	2579
2014 Q3	–	Sell	-484,400	Closed	-$14.2M	–	7187
2014 Q2	$14.2M	Sell	484,400 -88,800	-15%	-$2.85M	﹤0.01%	2080
2014 Q1	$25.3M	Buy	573,200 +337,700	+143%	+$14.9M	0.01%	1571
2013 Q4	$9.02M	Buy	235,500 +190,500	+423%	+$5.61M	﹤0.01%	2446
2013 Q3	$987K	Buy	+45,000	New	+$884K	﹤0.01%	4598

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Goldman Sachs's LAB Position: Q2 2026 in Review

Goldman Sachs reduced its Standard BioTools (LAB) stake by 77% in Q2 2026, selling an estimated $687K and leaving 216,422 shares worth $178K. The position accounts for ﹤0.01% of the portfolio, ranked #6228.

Goldman Sachs first reported a position in LAB in Q3 2013 and has held it in 48 quarters since. The position peaked at $8.88M in Q1 2024. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Goldman Sachs held 216,422 shares of Standard BioTools worth $178K as of Q2 2026.
Goldman Sachs sold 726,763 Standard BioTools shares in Q2 2026, an estimated $687K.
Standard BioTools made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6228 holding.
Goldman Sachs first reported a position in Standard BioTools in Q3 2013 and has held it in 48 quarters since.
Goldman Sachs's Standard BioTools position peaked at $8.88M in Q1 2024.
143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.